Phase 3, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan with Durvalumab +/- Chemotherapy followed by Adjuvant Durvalumab, Versus Neoadjuvant Pembrolizumab + Chemotherapy and Adjuvant Pembrolizumab, in Patients with Stage II-III Triple Negative Breast Cancer (TROPION-Breast04)

Principal Investigator

Dr Mark Henry Tuthill

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1008502